Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.
It also contains a sub-study to enroll patients with severe COVID-19.
DAS181 for Severe COVID-19: A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study
- ClinicalTrials.gov Identifier: NCT03808922
- Protocol Number: 2020P000352
- Principal Investigator: Chen Tan
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required